Amyris, Inc. (NASDAQ:AMRS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday. They currently have a $15.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 324.93% from the company’s previous close.

AMRS has been the topic of a number of other research reports. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Wednesday, October 4th. ValuEngine raised shares of Amyris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Cowen and Company set a $4.00 price target on shares of Amyris and gave the stock a “hold” rating in a research note on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.69.

Shares of Amyris (NASDAQ:AMRS) traded up $0.44 during midday trading on Wednesday, reaching $3.53. 731,104 shares of the company were exchanged, compared to its average volume of 260,584. The company has a current ratio of 0.65, a quick ratio of 0.56 and a debt-to-equity ratio of -0.76. Amyris has a 1 year low of $1.86 and a 1 year high of $14.85.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04). The business had revenue of $24.20 million for the quarter, compared to the consensus estimate of $36.30 million. The firm’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.07) earnings per share. sell-side analysts anticipate that Amyris will post -3.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Amyris, Inc. (AMRS) Rating Reiterated by HC Wainwright” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/amyris-inc-amrs-rating-reiterated-by-hc-wainwright/1710347.html.

Several hedge funds have recently modified their holdings of the company. Tanaka Capital Management Inc. raised its stake in shares of Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after acquiring an additional 221,295 shares during the period. KBC Group NV raised its stake in shares of Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 41,834 shares during the period. Carl Domino Inc purchased a new position in shares of Amyris in the 3rd quarter valued at $182,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 4,603 shares during the period. 19.99% of the stock is currently owned by institutional investors and hedge funds.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.